Trial · NCT03222609
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 32 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With ≥ 1 Grade Reduction From Baseline in Fibrosis Grade At Any Time | Navitoclax + Ruxolitinib (Cohort 1a) | Week 24 | 23.08 | 95% Confidence Interval 8.97 to 43.65 | percentage of participants |
| Percentage of Participants With ≥ 1 Grade Reduction From Baseline in Fibrosis Grade At Any Time | Navitoclax + Ruxolitinib (Cohort 1b) | Week 24 | 24.07 | 95% Confidence Interval 13.49 to 37.64 | percentage of participants |
| Percentage of Participants With ≥ 1 Grade Reduction From Baseline in Fibrosis Grade At Any Time | Navitoclax (Cohort 2) | Week 24 | 40.00 | 95% Confidence Interval 16.34 to 67.71 | percentage of participants |
| Percentage of Participants With ≥ 1 Grade Reduction From Baseline in Fibrosis Grade At Any Time | Navitoclax + Ruxolitinib (Cohort 3) | Week 24 | 30.43 | 95% Confidence Interval 13.21 to 52.92 | percentage of participants |
| Percentage of Participants With ≥ 1 Grade Reduction From Baseline in Fibrosis Grade At Any Time | Navitoclax + Ruxolitinib (Cohort 1a) | Anytime during the post-Baseline period | 41.94 | 95% Confidence Interval 24.55 to 60.92 | percentage of participants |
| Percentage of Participants With ≥ 1 Grade Reduction From Baseline in Fibrosis Grade At Any Time | Navitoclax + Ruxolitinib (Cohort 1b) | Anytime during the post-Baseline period | 41.56 | 95% Confidence Interval 30.43 to 53.36 | percentage of participants |
| Percentage of Participants With ≥ 1 Grade Reduction From Baseline in Fibrosis Grade At Any Time | Navitoclax (Cohort 2) | Anytime during the post-Baseline period | 40.91 | 95% Confidence Interval 20.71 to 63.65 | percentage of participants |
| Percentage of Participants With ≥ 1 Grade Reduction From Baseline in Fibrosis Grade At Any Time | Navitoclax + Ruxolitinib (Cohort 3) | Anytime during the post-Baseline period | 48.15 | 95% Confidence Interval 28.67 to 68.05 | percentage of participants |
| Time to First Reduction in Fibrosis Grade | Navitoclax + Ruxolitinib (Cohort 1a) | 24.1 | Full Range 11.1 to 107.1 | weeks | |
| Time to First Reduction in Fibrosis Grade | Navitoclax + Ruxolitinib (Cohort 1b) | 24.1 | Full Range 9.3 to 97.1 | weeks | |
| Time to First Reduction in Fibrosis Grade | Navitoclax (Cohort 2) | 12.4 | Full Range 11.9 to 48.1 | weeks | |
| Time to First Reduction in Fibrosis Grade | Navitoclax + Ruxolitinib (Cohort 3) | 12.3 | Full Range 7.0 to 96.1 | weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03222609/results?page=2